Washington: Researchers at Brigham and Women’s Hospital have found that two disease-modifying antirheumatic drugs (DMARDs) are associated with a reduced risk for the development of diabetes in psoriasis and rheumatoid arthritis patients.
They found that among patients with RA or psoriasis, the risk for developing diabetes was lower for those patients who started TNF inhibitor or hydroxychloroquine.
“While there may be other mechanisms at play in these medications aside from their effect on inflammation, we observed a reduced risk for diabetes in patients with RA or psoriasis who were treated with tumor necrosis factor (TNF) inhibitors or hydroxycholoriquine when compared with patients who began treatment on other non-biologic DMARDs,” said Daniel Solomon, lead author of the study.
For their findings, the researchers evaluated data gathered from 13,905 patients with RA or psoriasis with 22,493 new instances of treatment initiation.
The patients were categorized based on four categories of commonly used DMARD regimens: non-biologic DMARDs, TNF inhibitors, methotrexate and hydroxychloroquine.
Researchers reported that the rate of newly diagnosed diabetes was highest in individuals who were treated with nonbiologic DMARDs and lowest for TNF inhibitor users.
Additionally, when adjusting for other risk factors for diabetes, researchers found a reduced relative risk of diabetes in patients treated with TNF inhibitors and hydroxychloroquine compared with other non-biologic DMARDs.
The findings were published in the June 22/29, 2011 issue of the Journal of the American Medical Association.